Antibody Therapeutics Mouse Models

Humanized models express human target genes (receptors, checkpoint molecules, drug targets) to enable testing of clinical antibody candidates. Common targets include immune checkpoints (PD1, PDL1, CTLA4, LAG3), cytokine receptors, and disease-specific targets. Full gene humanization (complete human sequence) or ECD-only humanization (extracellular domain) are available.

Yes. Humanized checkpoint models can be combined with syngeneic tumor cell lines to create systems where both tumor and immune compartments express human targets. This enables evaluation of checkpoint blockade in immunocompetent animals with intact tumor immunity, providing more physiologically relevant testing.

Pre-germline characterization includes Southern blot analysis to confirm correct targeting and sequence verification to ensure human sequence fidelity. Post-germline validation includes flow cytometry for surface expression, Western blot for protein expression, and functional confirmation through binding of clinical antibody candidates.

Custom model generation includes targeting construct design, ES cell targeting, chimera generation, and germline transmission. Pre-germline characterization enables early validation of targeting and human sequence confirmation before mouse generation. Contact us for current timeline estimates.

Yes. We can combine multiple checkpoint humanizations (double, triple, or multi-checkpoint models) for combination immunotherapy studies. For example, PD1 and CTLA4 humanized models enable testing of dual checkpoint blockade. Multiple humanizations require careful breeding and genotyping to maintain all alleles.